Autoantibody Testing Strategy — SCE Rheumatology MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: E — Request ENA when clinical features give a reasonable pre-test probability of connective tissue disease
Explanation lettering: D = shown as A · A = shown as C · C = shown as D
E is correct: UK laboratory and referral guidance directs ANA and ENA testing by clinical suspicion of an ANA-associated connective tissue disease, not by an isolated serological result. ANA is sensitive but poorly specific, and low-titre positivity (1:80) occurs in 10–15% of healthy people, so in this woman with non-specific fatigue and pain, normal inflammatory markers, complement and urinalysis, an ENA panel has very low positive predictive value and risks incidental antibodies, further investigation and anxiety. B is wrong because reflex panels on every positive ANA generate false positives; C and D substitute an arbitrary titre threshold for clinical reasoning — high titre alone does not mandate ENA, and genuine anti-Ro or anti-Jo-1 disease can occur with modest titres. A delays nothing useful, since ANA positivity commonly persists in healthy individuals.
Reference: NHS North Central London ICB, "Right Test Right Time: Diagnostic blood test resource", section on ANA and anti-ENA testing (current). https://gps.northcentrallondon.icb.nhs.uk/right-test-right-time